Novo Nordisk A/S said its market research shows twice as many US Medicare recipients would rather take a weight-loss pill over a shot, a preference the Danish drugmaker will try to use to grab market share from its rival Eli Lilly & Co.
About three-quarters of Medicare recipients had a preference regarding whether to take a daily pill or weekly shot, US chief Jamey Millar said in an interview with Bloomberg TV. Of those, twice as many preferred a pill, he said.